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Abstract 
Background 
Heart failure (HF) is a burden to patients and health care systems. The objective of HF 
treatment is to improve health related quality of life (HRQoL) and reduce mortality 
and morbidity. We aimed to evaluate determinants of health-related quality of life 
(HRQoL) in patients with iron deficiency and HF treated with intravenous (i.v.) iron 
substitution or placebo. 
Methods 
A randomized, double-blind, placebo-controlled trial (N = 459) in iron-deficient 
chronic heart failure (CHF) patients with or without anaemia studied clinical and 
HRQoL benefits of i.v. iron substitution using ferric carboxymaltose (FCM) over a 
24-week trial period. Multivariate analysis was carried out with various clinical 
variables as independent and HRQoL measures as dependent variables. 
Results  
Mean change from baseline of European Quality of Life-5 Dimensions (EQ-5D) 
(value set-based) utilities (on a 0 to 100 scale) at week 24 was 8.91 (i.v. iron) and 0.68 
(placebo; p<0.01). In a multivariate analysis excluding baseline HRQoL, a higher 
exercise tolerance and i.v. iron substitution positively influenced HRQoL, whereas 
impaired renal function and a history of stroke had a negative effect. The level of 
HRQoL was also influenced by country of residence. When baseline HRQoL was 
factored in, the multivariate model remained stable. 
Conclusion 
In this study, i.v. iron substitution, exercise tolerance, stroke, country of residence and 
renal function influenced measures of HRQoL in patients with heart failure and iron 
deficiency. 
Introduction 
Heart failure (HF) is a leading cause of morbidity and mortality and poses a 
significant burden to health systems.1 It contributes to about 2% of all inpatient bed 
days and approximately 5% of all emergency medical admissions to hospitals in the 
United Kingdom (UK)2 and is the primary diagnosis on admission to German 
hospitals.3 The primary objective of HF treatment is to improve health-related quality 
of life (HRQoL) and reduce mortality and morbidity.2, 4 Previous multivariate 
analyses have reported New York Heart Association (NYHA) class, the 6-minute 
walk test and depression as predictors of HRQoL in HF patients.5-7 
In the cycle of oxygen uptake, transport and storage, iron plays an important role.8, 9 It 
has been shown that intravenous (i.v.) repletion of iron can diminish symptoms and 
improve HRQoL in chronic heart failure (CHF) patients.10-12 Treatment with ferric 
carboxymaltose (FCM), an i.v. iron preparation, resulted in improved HRQoL in 
FAIR-HF, an international (Table 1), randomized, double-blind, placebo-controlled 
trial (n = 459) that enrolled iron-deficient CHF patients with or without anaemia. 
Study patients were treated with i.v. iron substitution or placebo over the 24 week trial 
period.10 A recent analysis showed that in the FAIR-HF trial, mean utilities measured 
by the European Quality of Life-5 Dimensions (EQ-5D) questionnaire13 were higher 
in the i.v. iron substitution arm, resulting in an incremental cost-effectiveness ratio of 
3977 Pounds sterling (£), which was below the threshold of £20 000–£30 000 
typically used by the UK National Institute for Health and Clinical Excellence.14 
Health-state utilities are preference-based measures of HRQoL with a foundation in 
economic theory. They are frequently used in health economic analyses to calculate 
quality-adjusted life years (QALYs).15 The EQ-5D is a commonly used measure for 
this purpose.14 
This multivariate analysis further explores the EQ-5D-based utility effect observed in 
the i.v. iron substitution group of the FAIR-HF trial, by evaluating a wider range of 
determinants of HRQoL. The aim is to gain a better understanding of determinants of 
utility and HRQoL in CHF patients and to validate predictors of HRQoL previously 
identified from the FAIR-HF dataset in univariate analyses.16 
Methods 
This is a retrospective within-trial analysis of the FAIR-HF intention-to-treat (ITT) 
population including 459 patients with NYHA functional class II and III, an impaired 
left ventricular ejection fraction, and iron deficiency. Patients were randomly assigned 
to receive either i.v. iron substitution with FCM or placebo. During a correction 
phase, patients received weekly injections until iron repletion was achieved. A 
subsequent maintenance phase with 4-weekly injections followed. Further details 
were previously described.10, 17 Table 1 shows baseline demographic and clinical 
characteristics of the study population.  
All analyses were performed at the patient level following an a-priori specified 
analysis plan. Available data for independent variables were the data from FAIR-HF 
baseline assessments. Data for dependent variables were from the FAIR-HF 
assessments at week 24 (end of trial). HRQoL measures from FAIR-HF used for this 
analysis include EQ-5D-based utilities and the Kansas City Cardiomyopathy 
questionnaire (KCCQ)18 measurements at baseline and week 24. The main endpoint 
was EQ-5D-based utility measured at week 24. The secondary endpoint consisted of 
HRQoL represented by KCCQ summary score at week 24. In the case of missing 
values of single questionnaire items, the last recorded observation was imputed using 
the ‘last observation carried forward’ (LOCF) method. Patients with missing baseline 
information for a given endpoint, and patients with only baseline information, were 
excluded from the respective analyses. 
The EQ-5D is an instrument designed for self-completion by respondents. It 
comprises two parts: First, respondents report their health status according to a five-
dimensional classification including mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension is represented by a three 
level ordered category item, which leads to a total of 243 possible health ratings. In 
the current analysis, these ratings were valued using the standard European time 
trade-off value set to achieve utility estimates.19 Second, the respondents record their 
self-perceived health status using a graduated visual analogue scale (VAS), with 
grades from 0 meaning “death” to 100 meaning “perfect health”. The EQ-5D is a 
generic, i.e. non disease-specific HRQoL instrument which has been validated and 
shown to be sensitive, internally consistent, and reliable in the general population and 
different patient groups.20-22 The KCCQ is a self-administered, disease-specific 23-
item questionnaire for measuring HRQoL in patients with CHF. It quantifies physical 
function, symptoms (frequency, severity and recent change), social function, self-
efficacy and knowledge, and HRQoL.18 
Approach to covariate selection 
Available baseline variables from the FAIR-HF trial data were selected as candidate 
predictors (independent variables) if a potential influence on HRQoL could be 
assumed, i.e. if an association (e.g. clinical or biological) with the response variables 
(dependent variables, HRQoL outcomes) was expected on biological or clinical 
grounds. Factors selected as candidate predictors of HRQoL were demographic 
factors such as country of residence, age and gender; clinical factors, such as NYHA 
class at baseline, exercise tolerance (6-minute walk test), estimated glomerular 
filtration rate (eGFR) and depression (approximated by the EQ-5D anxiety/depression 
item), and medical history items, such as history of stroke, hypertension, angina 
pectoris and ischaemic heart disease and treatment regimen (for a complete list of 
candidate predictors please refer to Table 1). 
Statistical analysis 
Endpoints and covariates were described (Table 1); continuous and discrete numerical 
variables based on the mean with standard deviation (SD), median and range. Non-
plausible, outlying values were excluded from analysis. For binary and categorical 
variables, frequencies and percentages were used. All analyses were performed using 
Stata/MP 11 or Stata/SE 12 (StataCorp LP, College Station, TX, USA). 
Selection of candidate predictors for multivariate analysis (univariate analysis) 
Univariate analyses were performed depending on the underlying distribution of the 
involved variables. Based on graphical inspection, it was assumed that variables with 
small deviations from the normal distribution would not distort any results, thus they 
were treated as normally distributed. Associations of candidate predictors and the 
continuous endpoints were determined. For continuous predictors, Pearson (for linear 
association, assumption of normality) or Spearman rank (for monotone association, 
non-normality) correlations were performed to measure the strength of the 
association. Scatter plots were used to describe associations graphically (data on file). 
Given approximate normality of the endpoint variables, unpaired t-tests or ANOVA 
were performed to assess associations with binary or categorical predictors, 
respectively. All statistical tests were carried out two-sided at a 5% significance level, 
and 95% confidence intervals (CIs) were obtained, if applicable. Candidate predictors 
were further assessed in multivariate analysis if a trend was seen in univariate analysis 
(p ≤ 0.25). 
Multivariate analysis 
Normality of endpoint variables was assessed graphically using histograms. In the 
absence of relevant skewness, multivariate linear regression was used to assess the 
joint explanatory value of the candidate predictors. The analysis was carried out with 
and without HRQoL (EQ-5D utility or KCCQ score) at baseline. The rationale behind 
this approach is that an analysis without baseline HRQoL is more suitable for 
showing the influence of pre-existing factors (that might otherwise be absorbed into 
the effect of baseline HRQoL), whereas an analysis with baseline HRQoL better 
shows effects occurring after baseline and during the trial period. 
The selection process of potential predictors for the multivariate analysis was 
performed using both stepwise backward selection and stepwise forward selection 
procedures, results were compared for consistency. Decision criterion for variable 
selection into the final model was p ≤ 0.05. Interactions and collinearities between 
explanatory variables were assessed. To avoid over-modelling, significant interaction 
terms were to be included in final models only if they influenced the main effects 
substantially. Model fit was assessed using normal quantile plots of residuals and 
plots of residuals against explanatory variables and fitted values. The predictive 
ability of the final models and the explanatory value of the individual covariates were 
monitored using the adjusted R-squared statistic that shows the fraction of variance of 
the dependent variable that is explained by the model.  
For comparison, alternative multivariate regression models were also estimated using 
(a) EQ-5D VAS scores (instead of EQ-5D questionnaire-based utilities) at baseline as 
a predictor variable and (b) the log of the main endpoint variable (due to a slightly 
skewed distribution of the endpoint variable) and (c) the KCCQ score at week 24 as 
the endpoint (with and without baseline HRQoL). In the model with KCCQ as 
endpoint and baseline HRQoL, the EQ-5D anxiety/depression item (baseline value) 
was tested as an additional possible predictor. Because Russian and Ukrainian patients 
accounted for a large part of the patient population, the regression additionally was 
performed using a variable distinguishing Russian and Ukrainian patients from all 
others, instead of the variable representing individual countries that was otherwise 
used. 
Results 
Characteristics of the study patients 
Relevant clinical characteristics of the FAIR-HF ITT population of N = 459 patients 
are presented in Table 1 (for a consort diagram see Anker et al.10). Patients were 
enrolled from June 2007, through December 2008, in 75 sites in 11 countries.10 
 
*** 
Table 1 about here 
*** 
 
Description of endpoints 
In the analyses involving EQ-5D utilities, 7 observations with missing values at 
baseline were excluded from analysis. In the analyses additionally including EQ-5D 
VAS scores, 12 observations with missing values were excluded. In the case of the 
KCCQ summary score, exclusions amounted to 11 observations with missing values 
at baseline and 17 with values only for baseline. Both endpoints, EQ-5D utility and 
KCCQ summary score, indicated better HRQoL at week 24 than at baseline; the 
improvement was significantly higher in the i.v. iron substitution arm (Figure 1). 
Change from baseline for EQ-5D utility was 8.9 (i.v. iron; SD±22.43; 15%) and 0.7 
(Placebo; SD±21.15; 1%), respectively. For KCCQ summary scores change from 
baseline was 12.8 (i.v. iron; SD±21.22; 24%) and 6.2 (Placebo; SD±18.46; 12%), 
respectively (Figure 1). 
 
*** 
Figure 1 about here 
*** 
 
Predictors of EQ-5D utility 
A total of 20 candidate predictors showed a possible relationship with the main 
endpoint variable (p<0.25) in univariate analysis and were subsequently included in 
the multivariate analysis as possible determinants. The BMI variable only had p<0.25 
due to two outlying values (with BMI values of 48 and 49 kg/m2). BMI was thus not 
included in the multivariate analysis. 
Multivariate analysis without baseline HRQoL, which reflects influences of pre-
existing factors well, showed i.v. iron substitution, lower NYHA class and a better 
result in the 6-minute walk test to be associated with higher HRQoL; history of stroke 
and reduced renal function were associated with lower HRQoL (Table 2). There was 
also an effect of country of residence on HRQoL. Apart from country, i.v. iron 
substitution showed the strongest impact on the adjusted R-squared; which for the 
overall model was 0.17.  
 
*** 
Table 2 about here 
*** 
 
In the multivariate model including baseline HRQoL, which focuses on the influence 
of effects occurring after baseline, the effects of 6-minute walk test and NYHA class 
became non-significant. Other effects remained stable. (Table 2). This model had an 
adjusted R-squared of 0.32. 
 
When instead of single countries, Russian and Ukrainian patients were compared to 
the patients from all other countries, the effects of the other predictor variables 
remained stable (with and without baseline HRQoL). When the log of EQ-5D 
questionnaire-based utility or EQ-5D VAS scores were used as alternative endpoints, 
the effects of all predictor variables remained stable. This was also true when 
analysed without LOCF performed at EQ-5D item level. 
 
Predictors of KCCQ-based HRQoL 
The effects observed in the models of EQ-5D questionnaire-based utility remained 
stable when KCCQ summary scores from week 24 were used as the endpoint (Table 
3). 
When baseline KCCQ values were included, history of hypertension was observed as 
an additional determinant (p=0.03, coefficient 4.83) and the 6-minute walk test and 
NYHA class became non-significant. When, in addition to the baseline KCCQ values, 
the EQ-5D anxiety/depression item (baseline value) was included as a potential 
predictor, it was not significant. 
Significant interactions for the model with KCCQ baseline were found between i.v. 
iron substitution and KCCQ baseline. This interaction did not substantially improve 
the explanatory value of the model and was therefore not included in the final version. 
 
*** 
Table 3 about here 
*** 
 
Analysis of residuals did not indicate any issues with model specifications. 
Collinearities between explanatory variables were not found to be problematic in their 
respective context. 
 
Discussion 
Principal findings 
One important finding of the FAIR-HF trial was that i.v. iron substitution can improve 
HRQoL in iron deficient CHF patients.10, 16 In this additional within-trial study, we 
put this result into perspective by providing a broader analysis of correlates of 
HRQoL in this patient group. We found that i.v. iron substitution using FCM, lower 
NYHA class and a better result in the 6-minute walk test positively influenced 
HRQoL of HF patients, whereas impaired renal function and a history of stroke 
negatively affected HRQoL of HF patients. A further finding was that patients with a 
higher HRQoL at baseline were more likely to maintain or even improve their 
HRQoL over time. HRQoL levels differed between countries, which may be 
attributable to cultural differences, potential differences among the investigated 
collectives. The fact that the models did not change in relevant aspects when either 
EQ-5D utility or EQ-5D VAS scores were used, indicates that the observed inter-
country differences were most probably not due to issues related to either 
questionnaire comprehensibility or use of the European EQ-5D value set. However, 
given small patient numbers in some countries, the observed differences may partially 
be centre-effects in some countries. 
The distinct influence of NYHA class and exercise tolerance (6-minute walk test) on 
HRQoL observed in our results is in line with findings in the literature. 10, 5, 6, 23, 24 It 
has also been reported that kidney function is an important factor for a patients 
HRQoL, a result which we could reproduce in our model.25 The observation of a 
significant impact of history of stroke on HRQoL is also consistent with the 
literature.26, 27 History of ischaemic heart disease and hypertension had an effect on 
HRQoL in some sensitivity analyses. Such associations were also previously 
reported28, 29 and might have been stronger if the analysis had not been done in a 
population entirely affected by CHF. We could not confirm influences of gender, BMI 
or haemoglobin level, in contrast to previous reports based on univariate analysis.16, 30-
32 In contrast to findings in the literature7, depression, in our analysis represented by 
the EQ-5D anxiety/depression item, was not found to be a significant predictor of 
HRQoL expressed as KCCQ scores. This may have been due to simultaneous 
inclusion of baseline KCCQ as a predictor variable, as the EQ-5D anxiety/depression 
item would have been significant without baseline KCCQ. It should also be noted that 
this isolated use of an item of the EQ-5D, in the absence of a more suitable indicator 
of depression, is not a validated approach. 
Regarding the mechanisms through which the determinants we found may influence 
HRQoL, the primary pathway is most likely via direct improvement of physiological 
parameters, such as provision of oxygen to the body. It is possible that improvement 
of these parameters additionally influences the patients’ social activities and allows 
them to be more mobile and autonomous. With this in mind, monitoring of clinical 
signs and symptoms, and improving them where needed, should aim at restoring the 
social activities and contacts of patients, in order to improve their overall HRQoL. 
Limitations 
Our population consisted of CHF patients with iron deficiency; iron deficiency has 
been estimated to have a prevalence of <30% in anemic CHF patients33 and of nearly 
50% in unselected populations of stable CHF patients9. In populations different from 
the one analysed, with different proportions of iron-deficient patients, predictors of 
HRQoL and effect sizes might be different from our observed results. A further 
limitation of our study is that information on some possible determinants that might 
be important for a more complete understanding of the HRQoL of CHF patients was 
not available from the FAIR-HF data set. These determinants could include patients’ 
social status and social support received as well as  psychological well-being. The 
organisation of care and, specifically, participation in disease management 
programmes may also play a role. Dyspnoea, orthopnea, fatigue and peak oxygen 
uptake are further potential factors of relevance that were not available to us.5, 6 
The effect of i.v. iron substitution was observed during a limited treatment duration 
and we do not have any information on how sustainable this effect may be. Further 
research on the role of this treatment option should focus on investigating sustained 
effects of i.v. iron after substitution and under maintenance therapy. 
Conclusions 
In this study, i.v. iron substitution using FCM, NYHA class, stroke, country of 
residence, exercise tolerance and renal function influenced measures of HRQoL in 
CHF patients with iron deficiency. Determinants of HRQoL with easily measurable 
clinical correlates, such as kidney function and iron status, should be followed 
closely; stroke prevention, improvement of exercise tolerance and improvement in 
NYHA functional class should have high priority in clinical practice. Information on 
important determinants of HRQoL in CHF patients can help clinicians to identify 
those at risk of reduced HRQoL and to target interventions appropriately. 
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Tables  
Table 1. Baseline demographic and clinical characteristics of the FAIR-HF intention-to-treat 
population, according to study group. 
 Variable Ferric 
Carboxymaltose 
(N = 304) 
Placebo 
(N = 155) 
Demographics Age — years §§ 67.8±10.3 67.4±11.1 
Female sex §§ 159 (52.3) 85 (54.8) 
Country §§ 
Argentina 5 (1.6) 1 (0.6) 
Czech Republic 13 (4.3) 4 (2.6) 
Germany 8 (2.6) 3 (2.0) 
Spain 14 (4.6) 8 (5.2) 
Greece 6 (2.0) 5 (3.2) 
Italy 7 (2.3) 4 (2.6) 
Norway 0 (-) 2 (1.3) 
Poland 43 (14.1) 17 (11.0) 
Romania 10 (3.3) 6 (3.9) 
Russia 133 (43.7) 67 (43.2) 
Ukraine 65 (21.4) 38 (24.5) 
Employment status §§ 
Unemployed, employed or regularly 
retired 254 (83.6) 133 (86.0) 
Early retirement due to CHF 50 (16.4) 22 (14.2) 
Clinical 
characteristics 
Anaemic * 181 (59.5) 82 (53.0) 
NYHA class §§   
II 53 (17.4) 29 (18.7) 
III 251 (82.6) 126 (81.3) 
LVEF — %  31.9±5.5 33.0±6.1 
Heart rate — beats per minute § 70.9±11.4 71.9±11.7 
eGFR — mL/min §§ 63.7±21.2 64.8±25.3 
BMI — kg/m2 §§ 27.9±4.7 28.1±5.1 
Aetiology of CHF: ischaemic §§ 245 (80.6) 123 (79.4) 
6-minute walk test distance – meters §§ 274±105 269±109 
Concomitant medication 
Angiotensin receptor blocker § 33 (10.9) 22 (14.2) 
Angiotensin-converting-enzyme inhibitor 227 (74.7) 104 (67.1) 
Laboratory measurements 
Haemoglobin — g/L †§§ 119±12.6 119.5±13.8 
Serum ferritin — µg/L 52.5±54.5 60.1±66.5 
Transferrin saturation — % 17.7±12.6 16.7±8.4 
Risk factors / 
Medical History of… 
Smoking   
non smoker 225 (74.0) 114 (73.6) 
former smoker 56 (18.4) 27 (17.4) 
current smoker 23 (7.6) 14 (9.0) 
Hypertension (treated with drug) §§ 243 (79.9) 128 (82.6) 
Dyslipaemia (treated with drug) §§ 144 (47.4) 70 (45.2) 
Diabetes 93 (30.6) 37 (23.9) 
Myocardial infarction (MI) 168 (55.3) 90 (58.1) 
Angina pectoris § (AP) 171 (56.3) 89 (57.4) 
MI and AP § 95 (31.2) 57 (36.8) 
Stroke §§ 24 (7.9) 9 (5.9) 
Transient Ischemic Attack 9 (3.0) 6 (3.9) 
Valvular Heart Disease 85 (28.0) 48 (31.0) 
Atrial Fibrillation 94 (30.9) 44 (28.4) 
Procedures 
Coronary Angiography § 85 (28.0) 39 (25.2) 
Coronary Revascularization (CABG, 
PTCA) 
64 (21.0) 31 (20.0) 
HRQoL at 
baseline** 
EQ-5D utility 57.7±18.8 57.7±17.9 
EQ-5D VAS scores 54.3±17.1 54.1±15.2 
KCCQ  52.8±19.5 52.4±17.3 
Data presented are mean value ± SD or number (%) of patients. Values were calculated from the study data by 
the authors. In FAIR-HF a 2:1 randomisation was used10. 
* defined as Hb < 120 g/L for females and Hb< 130 g/L for males 
† Due to missing values, the N for haemoglobin are 298 (i.v. iron) and 153 (Placebo) 
§ Determinants chosen as candidate predictors in univariate analysis (p <= 0.25) 
§§ Determinants chosen as possible determinants for the multivariate analysis (p <= 0.05) 
** Due to missing values, the N for EQ-5D utility are 298 (i.v. iron) and 154 (Placebo); for EQ-5D VAS 
scores 295 (i.v. iron) and 152 (Placebo); for KCCQ 286 (i.v. iron) and 145 (Placebo) 
AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass graft; CHF, congestive heart 
failure; eGFR, estimated glomerular filtration rate; EQ-5D, European Quality of Life–5 Dimensions; g, gram; 
IDA, iron deficiency anaemia; KCCQ, Kansas City Cardiomyopathy questionnaire; LVEF, left ventricular 
ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PTCA, Percutaneous 
transluminal coronary angioplasty; µg, micrograms 
 
 
Table 2. Main effects model of EQ-5D at time point 24 weeks with and without baseline HRQoL 
(EQ-5D) 
 
Coefficient 95% CI p Coefficient 95% CI p 
Predictor	  
model without baseline HRQoL 
(n=459) 
model with baseline HRQoL 
(n=452) 
I.v. iron 7.98 3.80 ; 12.15 <0.01 8.12 4.38 ; 11.86 <0.01 
NYHA class 6.34 0.51 ; 12.18 0.03 - - - 
eGFR † 0.15 0.05 ; 0.24 <0.01 0.20 0.11 ; 0.23 <0.01 
Stroke -9.03 -16.71 ; -1.35 0.02 -8.62 -15.52 ; -1.71 0.02 
6-minute walk test 0.03 0.01 ; 0.05 0.02 - - - 
EQ5D utility baseline * - - - 0.57 0.47 ; 0.66 <0.01 
Poland Reference   Reference   
Argentina -0.09 -19.49 ; 19.32  0.99 4.01 -13.40 ; 21.42 0.65 
Czech Republic -9.76 -21.36 ; 1.84 0.09 -6.87 -17.20 ; 3.45 0.19 
Germany -20.83 -34.80 ; -6.87 <0.01 -19.77 -32.13 ; -7.40 <0.01 
Spain -7.00 -17.98 ; 3.98 0.21 -14.13 -24.05 ; -4.21 <0.01 
Greece -27.23 -42.25 ; -13.20 <0.01 -20.97 -33.25 ; -8.69 <0.01 
Italy -27.93 -41.90 ; -13.97 <0.01 -24.33 -36.63 ; -12.03 <0.01 
Norway -0.40 -30.89 ; 30.09 0.98 3.02 -24.01 ; 30.04 0.83 
Romania -0.53 -12.37 ; 11.30 0.93 -0.91 -11.48 ; 9.65 0.86 
Russia -18.95 -25.19 ; -12.71 <0.01 -16.97 -22.49 ; -11.45 <0.01 
Ukraine -19.11 -26.33 ; -11.88 <0.01 -15.75 -22.01 ; -9.49 <0.01 
Constant 54.63    27.26    
All countries combined: p < 0.01 
* Per increase by 1 
† for  a one unit increase in eGFR (mL/min) 
eGFR, estimated glomerular filtration rate; i.v., intravenous 
Table 3. Effects model of KCCQ at time point 24 weeks with and without baseline HRQoL 
 Coef. 95% CI p Coef. 95% CI p 
Predictor 
model without baseline HRQoL 
(n=425) 
model with baseline HRQoL 
(n=448) 
I.v. iron 6.67 2.80 ; 10.54 <0.01 6.60 3.17 ; 10.03 <0.01 
NYHA class 11.15 5.74 ; 16.56 <0.01 - - - 
eGFR † 0.16 0.07 ; 0.25 <0.01 0.20 0.12 ; 0.27 <0.01 
Stroke -7.42 -14.46 ; -0.37 0.04 -7.29 -13.56 ; -1.03 0.02 
6-minute walk test 0.03 0.01 ; 0.05 0.01 - - - 
Hypertension - - - 4.83 0.49 ; 9.17 0.03 
KCCQ baseline * - - - 0.56 0.48 ; 0.65 <0.01 
Poland Reference   Reference   
Argentina 4.43 -15.00 ; 23.86 0.65 -0.41 -17.78 ; 16.95 0.96 
Czech Republic -6.00 -16.47 ; 4.48 0.26 -11.69 -21.05 ; -2.34 0.01 
Germany -17.22 -29.84 ; 4.60 <0.01 -20.97 -32.11 ; -9.84 <0.01 
Spain -10.42 -22.53 ; 1.69 0.09 -20.36 -31.26 ; -9.45 <0.01 
Greece -23.43 -37.10 ; -9.75 <0.01 -18.21 -29.63 ; -6.79 <0.01 
Italy -18.74 -31.36 ; -6.12 <0.01 -16.93 -28.00 ; -5.87 <0.01 
Norway -5.04 -32.59 ; 22.51 0.72 -9.16 -33.40 ; 15.08 0.46 
Romania 5.44 -5.51 ; 16.39 0.33 0.65 -9.06 ; 10.37 0.90 
Russia -17.55 -23.23 ; -11.88 <0.01 -18.76 -23.92 ; -13.60 <0.01 
Ukraine -15.93 -22.48 ; -9.38 <0.01 -17.42 -23.13 ; -11.70 <0.01 
Constant 53.35   27.63   
All countries combined: p < 0.01 
* Per increase by 1 
† for  a one unit increase in eGFR (mL/min) 
eGFR, estimated glomerular filtration rate; i.v., intravenous; TSAT, transferrin saturation 
 
Figure legend 
Figure 1. Boxplot showing median, range, interquartile range and outliers of the mean 
EQ-5D utility and KCCQ summary score at baseline and week 24. 
 
Figure 
Figure 1. Boxplot showing median, range, interquartile range and outliers of the mean EQ-5D 
utility and KCCQ values at baseline and week 24. 
 
 
